Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin’s Lymphoma

Overview of attention for article published in Clinical Pharmacokinetics, September 2012

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 31 Dimensions

Readers on

mendeley: 41 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 0 followers.

Giving Velcade to #myeloma patients with strong CYP3A4 inducer such as rifampicin may reduce the clinical effect (http://t.co/hZzZMzgG).

Reply Repost Favourite